Cargando…

Long-Term Outcome Measures of Repeated Non-Animal Stabilized Hyaluronic Acid (Durolane) Injections in Osteoarthritis: A 6-Year Cohort Study with 623 Consecutive Patients

PURPOSE: To determine the duration of symptom relief following repeated administration of hyaluronic acid injections for osteoarthritis. PATIENTS AND METHODS: This was a 6-year observational study with 623 consecutive patients who had received hyaluronic acid injections. The primary outcome measure...

Descripción completa

Detalles Bibliográficos
Autores principales: Carney, Georgia, Harrison, Andrew, Fitzpatrick, Jane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457651/
https://www.ncbi.nlm.nih.gov/pubmed/34566438
http://dx.doi.org/10.2147/OARRR.S331562
_version_ 1784571145360506880
author Carney, Georgia
Harrison, Andrew
Fitzpatrick, Jane
author_facet Carney, Georgia
Harrison, Andrew
Fitzpatrick, Jane
author_sort Carney, Georgia
collection PubMed
description PURPOSE: To determine the duration of symptom relief following repeated administration of hyaluronic acid injections for osteoarthritis. PATIENTS AND METHODS: This was a 6-year observational study with 623 consecutive patients who had received hyaluronic acid injections. The primary outcome measure was the mean time between injections measured in days. Classical one-sample 2-sided t-tests, one-way analysis of variances and post-hoc analyses were performed to determine if there were statistically significant differences between age, gender, radiographic severity and the type of joints injected. All patients were invited to complete an online post-treatment experience and satisfaction survey. RESULTS: The analysis included 727 joints (mean Kellgren-Lawrence grade, 2.9 ± 0.8 (range 2–4)) in 623 patients (297 (47.7%) male; mean age at first injection, 57.8 ± 12.7 years (range 21.2–92.1)). Patients ranged from having 1–8 injections per joint. The mean time between injections in days was 466.8 ± 321.7 (2nd injection, 157 joints), 400.5 ± 164.7 (3rd injection, 58 joints), 378.2 ± 223.1 (4th injection, 27 joints), 405.3 ± 216.3 (5th injection, 7 joints), 268.4 ± 104.4 (6th injection, 5 joints), 289.8 ± 99.4 (7th injection, 4 joints), and 272.5 ± 33.2 (8th injection, 2 joints). Patients with grades 2 and 3 compared to grade 4 osteoarthritis experienced a longer time between injections (F (2, 154) = 3.53, p = 0.0316). No statistically significant differences were observed between age, gender, or joint groups. The survey included 233 participants (109 (46.8% male)). A total of 144 respondents (64.9%) recommended hyaluronic acid injections for osteoarthritis. CONCLUSION: Pain relief from hyaluronic acid injections was sustained for on average 466.8 days post initial treatment. Patients who received subsequent 3rd, 4th, and 5th injections also experienced extended duration of benefit. Patients with grades 2 or 3 osteoarthritis are more likely to experience a longer duration of relief.
format Online
Article
Text
id pubmed-8457651
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84576512021-09-23 Long-Term Outcome Measures of Repeated Non-Animal Stabilized Hyaluronic Acid (Durolane) Injections in Osteoarthritis: A 6-Year Cohort Study with 623 Consecutive Patients Carney, Georgia Harrison, Andrew Fitzpatrick, Jane Open Access Rheumatol Original Research PURPOSE: To determine the duration of symptom relief following repeated administration of hyaluronic acid injections for osteoarthritis. PATIENTS AND METHODS: This was a 6-year observational study with 623 consecutive patients who had received hyaluronic acid injections. The primary outcome measure was the mean time between injections measured in days. Classical one-sample 2-sided t-tests, one-way analysis of variances and post-hoc analyses were performed to determine if there were statistically significant differences between age, gender, radiographic severity and the type of joints injected. All patients were invited to complete an online post-treatment experience and satisfaction survey. RESULTS: The analysis included 727 joints (mean Kellgren-Lawrence grade, 2.9 ± 0.8 (range 2–4)) in 623 patients (297 (47.7%) male; mean age at first injection, 57.8 ± 12.7 years (range 21.2–92.1)). Patients ranged from having 1–8 injections per joint. The mean time between injections in days was 466.8 ± 321.7 (2nd injection, 157 joints), 400.5 ± 164.7 (3rd injection, 58 joints), 378.2 ± 223.1 (4th injection, 27 joints), 405.3 ± 216.3 (5th injection, 7 joints), 268.4 ± 104.4 (6th injection, 5 joints), 289.8 ± 99.4 (7th injection, 4 joints), and 272.5 ± 33.2 (8th injection, 2 joints). Patients with grades 2 and 3 compared to grade 4 osteoarthritis experienced a longer time between injections (F (2, 154) = 3.53, p = 0.0316). No statistically significant differences were observed between age, gender, or joint groups. The survey included 233 participants (109 (46.8% male)). A total of 144 respondents (64.9%) recommended hyaluronic acid injections for osteoarthritis. CONCLUSION: Pain relief from hyaluronic acid injections was sustained for on average 466.8 days post initial treatment. Patients who received subsequent 3rd, 4th, and 5th injections also experienced extended duration of benefit. Patients with grades 2 or 3 osteoarthritis are more likely to experience a longer duration of relief. Dove 2021-09-18 /pmc/articles/PMC8457651/ /pubmed/34566438 http://dx.doi.org/10.2147/OARRR.S331562 Text en © 2021 Carney et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Carney, Georgia
Harrison, Andrew
Fitzpatrick, Jane
Long-Term Outcome Measures of Repeated Non-Animal Stabilized Hyaluronic Acid (Durolane) Injections in Osteoarthritis: A 6-Year Cohort Study with 623 Consecutive Patients
title Long-Term Outcome Measures of Repeated Non-Animal Stabilized Hyaluronic Acid (Durolane) Injections in Osteoarthritis: A 6-Year Cohort Study with 623 Consecutive Patients
title_full Long-Term Outcome Measures of Repeated Non-Animal Stabilized Hyaluronic Acid (Durolane) Injections in Osteoarthritis: A 6-Year Cohort Study with 623 Consecutive Patients
title_fullStr Long-Term Outcome Measures of Repeated Non-Animal Stabilized Hyaluronic Acid (Durolane) Injections in Osteoarthritis: A 6-Year Cohort Study with 623 Consecutive Patients
title_full_unstemmed Long-Term Outcome Measures of Repeated Non-Animal Stabilized Hyaluronic Acid (Durolane) Injections in Osteoarthritis: A 6-Year Cohort Study with 623 Consecutive Patients
title_short Long-Term Outcome Measures of Repeated Non-Animal Stabilized Hyaluronic Acid (Durolane) Injections in Osteoarthritis: A 6-Year Cohort Study with 623 Consecutive Patients
title_sort long-term outcome measures of repeated non-animal stabilized hyaluronic acid (durolane) injections in osteoarthritis: a 6-year cohort study with 623 consecutive patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457651/
https://www.ncbi.nlm.nih.gov/pubmed/34566438
http://dx.doi.org/10.2147/OARRR.S331562
work_keys_str_mv AT carneygeorgia longtermoutcomemeasuresofrepeatednonanimalstabilizedhyaluronicaciddurolaneinjectionsinosteoarthritisa6yearcohortstudywith623consecutivepatients
AT harrisonandrew longtermoutcomemeasuresofrepeatednonanimalstabilizedhyaluronicaciddurolaneinjectionsinosteoarthritisa6yearcohortstudywith623consecutivepatients
AT fitzpatrickjane longtermoutcomemeasuresofrepeatednonanimalstabilizedhyaluronicaciddurolaneinjectionsinosteoarthritisa6yearcohortstudywith623consecutivepatients